Gallium Maltolate CAS 108560-70-9
Identification
CAS Number
108560-70-9
Name
Gallium Maltolate
Synonyms
108560-70-9 [RN]
4H-Pyran-4-one, 3-hydroxy-2-methyl-, gallium salt (3:1) [ACD/Index Name]
GALLIUM MALTOLATE
Gallium tris(2-methyl-4-oxo-4H-pyran-3-olate) [ACD/IUPAC Name]
Galliumtris(2-methyl-4-oxo-4H-pyran-3-olat) [German] [ACD/IUPAC Name]
Tris(2-méthyl-4-oxo-4H-pyran-3-olate) de gallium [French] [ACD/IUPAC Name]
3-Bis[(2-methyl-4-oxopyran-3-yl)oxy]gallanyloxy-2-methylpyran-4-one
SMILES
Cc1c(c(=O)cco1)[O-].Cc1c(c(=O)cco1)[O-].Cc1c(c(=O)cco1)[O-].[Ga+3]
StdInChI
InChI=1S/3C6H6O3.Ga/c31-4-6(8)5(7)2-3-9-4;/h32-3,8H,1H3;/q;;;+3/p-3
StdInChIKey
ASYYOZSDALANRF-UHFFFAOYSA-K
Molecular Formula
C18H15GaO9
Molecular Weight
445.029
Properties
Appearance
Off-white or light pink powder
Safety Data
RIDADR
NONH for all modes of transport
WGK Germany
3
Specifications and Other Information of Our Gallium Maltolate CAS 108560-70-9
Identification Methods
HNMR
Purity
98% min
Ga
15%min
Shelf Life
2 years
Storage
Under room temperature away from light
Advantage
Gallium maltolate, by offering the advantages of enhanced bioavailability, potentially improved therapeutic properties and ease of administration, could significantly expand the therapeutic potential of gallium. To investigate the use/treatment of bladder cancer, lymphoma (not specified), multiple myeloma, paging disease and prostate cancer.
Known Application
Gallium maltolate is a novel active formulation of gallium, a semimetal element, and a potent inhibitor of ribonucleotide reductase, an enzyme that promotes tumor growth. Gallium is also thought to concentrate in malignancies and sites of infection, and appears to favorably affect calcium deposition, making bones more resistant to degradation caused by cancer metastases.
Links
This product is developed by our R&D company Caming Pharmaceutical Ltd (https://www.caming.com/).
This product is developed by our R&D company Watson International Ltd (https://www.watson-int.com/).